TXG Stock Climbs As Wall Street Hikes Price Targets

10x Genomics Inc. stocks have been trading up by 12.76 percent following upbeat coverage of its expanding single-cell technology adoption

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TXG

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Barclays lifted its TXG price target from $30 to $40 and kept an Overweight call, flagging improving sentiment across life science tools and room for modest earnings beats.
Citi boosted its 10x Genomics price target from $24 to $45 while staying Neutral, signaling better perceived upside but also lingering caution.
A planned acquisition of Proteintech Genomics adds high‑plex proteomic tools, including the Human Discovery Panel, with limited near‑term financial impact for TXG.
A multi‑year Cleveland Clinic collaboration puts TXG’s Flex Apex, Xenium, and Atera platforms into advanced bladder cancer research, expanding long‑run oncology potential.
CEO Serge Saxonov sold 30,000 TXG shares for about $1.03M on 2026/06/22 but still controls roughly 1.39M Class A shares.

Live Update At 12:32:43 EDT: On Thursday, July 09, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 12.76%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TXG has been acting like a growth name coming back into favor. Over the last few weeks, 10x Genomics has climbed from a close of $29.73 on 2026/06/15 to $42.25 on 2026/07/09. That’s a strong rebound, with TXG grinding higher almost day after day. The most recent session shows a push from a $38.33 open to a close above $42, a breakout-style move that momentum traders watch closely.

Intraday, TXG traded in a tight but rising channel, holding above $41 for most of the session and topping out near $42.67. That steady bid suggests dip buyers are active and shorts are backing off. From a fundamentals angle, 10x Genomics posted about $150.8M in quarterly revenue with a solid 69.6% gross margin, but it still runs a net loss of roughly $13.5M. TXG has about $490.3M in cash and modest long‑term debt near $70.1M, giving the company plenty of runway.

More Breaking News

For traders, that mix—strong top‑line growth, negative earnings, and a big cash cushion—screams “story stock.” The chart is telling you where sentiment is shifting faster than the income statement.

Why Traders Are Watching TXG Right Now

TXG has a rare setup that many active traders hunt for: strong news catalysts lining up with a bullish chart. On the news side, 10x Genomics just grabbed headlines with its plan to acquire Proteintech Genomics. The deal adds high‑plex proteomic tools, including the Human Discovery Panel, into TXG’s single‑cell and spatial biology platforms. Management is clear this will not move near‑term numbers much, but for the story, it’s big. It deepens the TXG ecosystem and gives labs one more reason to stay inside the company’s workflow.

At almost the same time, 10x Genomics announced a multi‑year collaboration with Cleveland Clinic. The project will use TXG’s Flex Apex, Xenium, and later Atera systems to study advanced bladder cancer and hunt for biomarkers that could support future oncology diagnostics. That is powerful validation. For traders, TXG partnering with a top‑tier medical center screams institutional confidence and long‑horizon optionality.

Wall Street is responding. Barclays raised its TXG target from $30 to $40 and kept an Overweight rating, saying sentiment across life science tools is improving and Q2 prints should at least meet expectations. Then Citi came in even higher, hiking its TXG target from $24 to $45, though it stayed Neutral. Put those together and you have a clear message: the Street now sees more upside than it did a few months ago, even if not everyone is ready to pound the table.

One wrinkle: CEO Serge Saxonov sold 30,000 TXG shares for about $1.03M on 2026/06/22. That kind of insider sale can spook fast‑money traders, but he still holds roughly 1.39M Class A shares, so his skin in the game remains large. Net‑net, the flow of news leans bullish, and the price action confirms it.

Conclusion

TXG is a classic momentum‑meets‑story setup that active traders love to study. The stock has ripped from the low $30s to the low $40s in a few weeks while 10x Genomics has stacked real catalysts: the Proteintech Genomics acquisition to boost proteomics, the Cleveland Clinic collaboration to extend into oncology diagnostics, and two price target hikes that reframe where Wall Street thinks TXG belongs.

Under the hood, 10x Genomics is still losing money, but it carries almost half a billion dollars in cash, strong gross margins, and low leverage. That gives TXG time to turn today’s research and platform deals into tomorrow’s revenue. For traders, the key is to respect both sides of that coin—big upside potential paired with real execution risk.

Short term, the uptrend in TXG is clear. The daily chart shows higher lows, breakout closes, and strong intraday support around prior resistance. That’s the type of action momentum traders lean into, but only with strict risk control. As Tim Bohen, lead trainer with StocksToTrade says, “For me, trading is more about managing risk than finding the next big mover.” As Tim Sykes likes to say, “Cut losses quickly, because big losses come from small ones you refuse to take.” TXG is offering a clean trading lesson right now: follow the catalysts, follow the chart, and always respect your stop. This analysis is for educational and research purposes only, not a recommendation to buy or sell TXG.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!